Pharmacovigilance of Chinese Medicine in Medical Institutions

doi:10.19803/j.1672-8629.2021.06.12

Abstract

Abstract: Objective To explore theories of pharmacovigilance of traditional Chinese medicine (TCM) in medical institutions in order to provide reference for related pharmacovigilance. Methods The definitions and evolution of pharmacovigilance of TCM were summarized. Traditional theories of pharmacovigilance and the realities in medical institutions in China were taken into consideration. The priorities of TCM pharmacovigilance were outlined. Results Medical institutions should not only supervise the quality and safety of traditional Chinese medicine during pharmacovigilance, but also promote clinical pharmacy services related to TCM. Standard methods should be employed to assess the safety of TCM while therapeutic drugs of TCM should be constantly monitored to create an atmosphere for pharmacovigilance. Conclusion Medical institutions cannot keep improving pharmacovigilance of TCM unless the safety of TCM takes center stage.

Key words: traditional Chinese medicine, pharmacovigilance, medical institutions, safe medication, Chinese pharmacist, clinical pharmacy service

CLC Number:

R994.11

GENG Hongjiao, WANG Lianxin, XIE Yanming. Pharmacovigilance of Chinese Medicine in Medical Institutions[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 552-555.

References

[1] Wang T, Wang D, Dong D.Thinking on the construction of China's pharmacovigilance system[J].China Food and Drug Administration(中国食品药品监管), 2019(1):37-41.
[2] Feng YN, Liu XX, Li YH, et al.Challenges faced by medical institutions' pharmacovigilance work under the new "Drug Administration Law"[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 572-573, 582.
[3] Song CY, Wang XN, Xin L.Innovative drug supervision methods to create a new pattern of smart supervision[J]. China Food and Drug Administration(中国食品药品监管), 2020(3): 54-59.
[4] Yuan L, Gao Y, Lu CF.Preliminary thinking on establishing a pharmacovigilance system in my country[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 749-752.
[5] Zhang J, Fu W, Wang JK.The status and role of medical institutions in pharmacovigilance[J]. China Pharmacy(中国药房), 2009, 20(2): 81-83.
[6] Su YK.Discussion on my country's pharmacovigilance system[J]. Tianjin Pharmacy(天津药学), 2013, 25(1): 61-63.
[7] Shen Q, Zhang L, Yan SY, et al.The role of pharmacovigilance system in the safe use of drugs in medical institutions[J]. China Pharmacy(中国药房), 2012, 23(10): 865-867.
[8] Wu GS.The main problems and countermeasures of adverse drug reaction monitoring in our hospital[J].China Pharmacy(中国药房), 2007(8): 619-620.
[9] Peng LL, Fan Y, Liu W, et al.Discuss how pharmaceutical manufacturers establish a pharmacovigilance system[J]. Chinese Pharmacovigilance(中国药物警戒), 2017, 14(11): 666-670.
[10] Ma S.Analysis and countermeasures of problems in quality management of traditional Chinese medicine decoction pieces in hospital Chinese pharmacies[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine in Cardiovascular Diseases(中西医结合心血管病电子杂志), 2020, 8(35): 190-191.
[11] Huang X.Research on the storage and maintenance of chinese herbal pieces[J]. Asia-Pacific Traditional Medicine(亚太传统医药), 2013, 9(11): 202-203.
[12] Zeng FD.Pharmacovigilance and clinical pharmacy services[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2014, 23(12): 718-721.
[13] Wu JY, Zhang M, Wang RL, et al. Constructing the knowledge system of surgical pharmacists-surgical pharmacy [J/OL]. Pharmacy Today(今日药学): (2020-12-01) [2020-12-04]. http://kns.cnki.net/ kcms/detail/44.1650.R.20201201.1013.002.html.
[14] Lin ZJ, Zhang B.Introduction to the practice training model of Mayo clinical pharmacists and its enlightenment to the training of clinical Chinese pharmacists in my country[J]. Education of Chinese Medicine(中医教育), 2019, 38(4): 31-34.
[15] Shi CX, Tian MD, Shi JJ, et al.Types and causes analysis of unreasonable prescriptions of traditional Chinese medicine in a hospital[J]. Chinese Medical Guide(中国医药指南), 2020, 18(10): 168-169, 172.
[16] Zhou MH, Wu XL, Zhang JF.A comparative study of clinical pharmacists participating in the formulation and implementation of orthopedic TCM clinical pathways[J]. Chinese Pharmacist(中国药师), 2017, 20(12): 2180-2182,2189.
[17] Xing J.Research on the effect of traditional Chinese medicine and pharmaceutical services in reducing adverse reactions of traditional Chinese medicine[J]. Psychological Monthly(心理月刊), 2018(4): 44-45.
[18] Gao J.The professional status of clinical pharmacists in pharmaco-vigilance[J]. China Pharmaceuticals(中国药业), 2016, 25(19): 77-79.
[19] Xie YM.Evidence-based research and practice on the safety of traditional Chinese medicine(循证中医药安全性证据研究与实践) [M]. Beijing: People's Medical Publishing House, 2019: 190.
[20] Tao QM, Zhan SY.Application of prescription sequence analysis and prescription sequence symmetry analysis in pharmacoe-pidemiology[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2012, 21(10): 517-519.
[21] Zhou YF, Cheng YC, Gao SQ, et al.Taking Xiyanping injection as an example to explore the ability of prescription sequence symmetry analysis to detect allergic signals[J]. Journal of Pharmaceutical Epidemiology(药物流行病学杂志), 2019, 28(6): 376-379, 388.
[22] Li N.The status quo and prospect of modern traditional Chinese medicine pharmacokinetics research and therapeutic drug monitoring based on "syndrome, medicine and effect"[J]. Chinese Pharmacist(中国药师), 2015, 18(7): 1140-1144.
[23] Liu CX.Practical pharmacokinetics(实用药物动力学)[M].Beijing: China Medical Science and Technology Press, 2003: 274.
[24] Wang YH, Chen TC, Pan HB.Drawing on the experience of western medicine clinical pharmacy to develop traditional Chinese medicine clinical pharmacy[J]. Chinese Pharmaceutical Affairs(中国药事), 1997, 11(4): 269.
[25] Xu HX.Toxicity and prevention of Chinese medicine Maqianzi[J].Information on Traditional Chinese Medicine(中医药信息), 2005, 5: 87.
[26] Shen YJ.Pharmacology of traditional Chinese medicine(中药药理学)[M]. Shanghai: Shanghai Science and Technology Press, 1997: 32, 189.
[27] Li DX.Analysis of the causes of adverse reactions of traditional Chinese medicine[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2004, 15(11): 803.
[28] Xu JY.The main causes and countermeasures of adverse reactions of traditional Chinese medicine[J]. Chinese Medicine and Materia Medica(中医中药), 2006, 3(11) :121.
[29] Feng YF, Liu PL, Li QH.The current situation and prospects of the monitoring of traditional Chinese medicine therapy[J]. Lishizhen Medicine and Materia Medica(时珍国医国药), 2007(5): 1255-1256.